Syngen BiotechLtd Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Syngen BiotechLtd.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	59.5%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Is Syngen Biotech Co., Ltd.'s (GTSM:8279) Latest Stock Performance Being Led By Its Strong Fundamentals?

Jan 14

Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly

Dec 16

Syngen Biotech's (GTSM:8279) Earnings Are Growing But Is There More To The Story?

Nov 25

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Syngen BiotechLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TPEX:8279 - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	2,000	239	251	342	N/A
6/30/2024	1,916	237	278	372	N/A
3/31/2024	1,861	262	261	354	N/A
12/31/2023	1,837	275	321	415	N/A
9/30/2023	1,890	287	294	363	N/A
6/30/2023	1,961	308	287	370	N/A
3/31/2023	1,996	329	-237	354	N/A
12/31/2022	1,931	321	-307	277	N/A
9/30/2022	1,848	319	-258	328	N/A
6/30/2022	1,655	296	-294	279	N/A
3/31/2022	1,545	262	226	300	N/A
12/31/2021	1,471	238	275	336	N/A
9/30/2021	1,372	212	287	357	N/A
6/30/2021	1,363	203	77	251	N/A
3/31/2021	1,349	217	76	283	N/A
12/31/2020	1,311	216	-53	220	N/A
9/30/2020	1,310	225	-138	147	N/A
6/30/2020	1,317	211	-18	172	N/A
3/31/2020	1,301	195	-5	145	N/A
12/31/2019	1,297	189	148	255	N/A
9/30/2019	1,281	181	124	211	N/A
6/30/2019	1,242	184	84	171	N/A
3/31/2019	1,152	153	55	129	N/A
12/31/2018	1,080	134	-27	67	N/A
9/30/2018	997	116	-20	74	N/A
6/30/2018	959	126	N/A	89	N/A
3/31/2018	944	143	N/A	197	N/A
12/31/2017	956	149	N/A	161	N/A
9/30/2017	934	145	N/A	90	N/A
6/30/2017	872	117	N/A	86	N/A
3/31/2017	809	96	N/A	41	N/A
12/31/2016	769	90	N/A	47	N/A
9/30/2016	731	79	N/A	81	N/A
6/30/2016	673	68	N/A	67	N/A
3/31/2016	639	65	N/A	77	N/A
12/31/2015	644	67	N/A	95	N/A
9/30/2015	626	67	N/A	100	N/A
6/30/2015	626	59	N/A	77	N/A
3/31/2015	600	45	N/A	75	N/A
12/31/2014	556	35	N/A	49	N/A
9/30/2014	476	22	N/A	33	N/A
6/30/2014	395	9	N/A	18	N/A
3/31/2014	335	12	N/A	17	N/A
12/31/2013	275	15	N/A	16	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 8279's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if 8279's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 8279's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 8279's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 8279's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 8279's Return on Equity is forecast to be high in 3 years time

Syngen BiotechLtd Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Third quarter 2024 earnings released: EPS: NT$2.67 (vs NT$2.59 in 3Q 2023)

Second quarter 2024 earnings released: EPS: NT$1.83 (vs NT$2.76 in 2Q 2023)

Investor sentiment deteriorates as stock falls 18%

Upcoming dividend of NT$5.00 per share

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: EPS exceeds analyst expectations

Syngen Biotech Co.,Ltd., Annual General Meeting, May 29, 2024

Third quarter 2023 earnings released: EPS: NT$2.59 (vs NT$3.37 in 3Q 2022)

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of NT$5.00 per share at 2.9% yield

Full year 2022 earnings released: EPS: NT$11.85 (vs NT$8.77 in FY 2021)

No independent directors

Third quarter 2022 earnings released: EPS: NT$3.37 (vs NT$2.54 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of NT$4.00 per share

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

No independent directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS NT$2.54 (vs NT$2.20 in 3Q 2020)

Upcoming dividend of NT$3.50 per share

Second quarter 2021 earnings released: EPS NT$2.25 (vs NT$2.75 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$1.53 (vs NT$1.48 in 1Q 2020)

Does Syngen BiotechLtd (GTSM:8279) Have A Healthy Balance Sheet?

Full year 2020 earnings released: EPS NT$7.95 (vs NT$7.86 in FY 2019)

Syngen Biotech Co., Ltd., Annual General Meeting, May 28, 2021

New 90-day high: NT$113

Should Syngen Biotech Co., Ltd. (GTSM:8279) Be Part Of Your Dividend Portfolio?

Did You Miss Syngen Biotech's (GTSM:8279) Impressive 104% Share Price Gain?

Is Syngen Biotech Co., Ltd.'s (GTSM:8279) Latest Stock Performance Being Led By Its Strong Fundamentals?

New 90-day low: NT$107

Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly

Syngen Biotech's (GTSM:8279) Earnings Are Growing But Is There More To The Story?

Third quarter earnings released

New 90-day low: NT$107

First half earnings released

New 90-day high - NT$130

First half earnings released

New 90-day high - NT$120

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies